查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1606524

日本核子医学市场 - 2024-2031

Japan Nuclear Medicine Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

日本核子医学市场在 2023 年达到 5.503 亿美元，预计到 2031 年将达到 25.432 亿美元，2024-2031 年预测期间复合年增长率为 21.2%。

核子医学是利用放射性示踪剂（称为放射性药物）来评估身体功能并诊断或治疗疾病的医学专业。专用影像相机使医生能够监测这些放射性示踪剂在体内的运动。核子医学中最受欢迎的两种影像技术是单光子发射电脑断层扫描 (SPECT) 和正电子发射断层扫描 (PET) 扫描。

SPECT 影像设备产生三维（断层扫描）影像，显示引入病患体内的放射性追踪剂分子的分布。这些 3D 影像是透过电脑处理从身体周围各个角度捕获的大量投影影像而创建的。 SPECT 成像仪配备了伽马相机探测器，可识别对患者施用的示踪剂发出的伽马射线。

PET 扫描也利用放射性药物产生三维影像。 SPECT 和 PET 扫描之间的主要区别在于所使用的放射性追踪剂的类型。 SPECT 扫描可侦测伽玛射线，而 PET 扫描中使用的放射性追踪剂在衰变时产生称为正电子的小粒子。正电子是一种质量与电子相似但带有相反电荷的粒子。这些因素推动了日本核子医学市场的扩张。

市场动态：

驱动程式和限制

癌症和心臟病的盛行率不断增加

癌症和心臟病患病率的不断上升极大地推动了日本核医学市场的成长，预计将在整个市场预测期内推动成长。

癌症和心血管疾病发生率的增加是核医市场成长的重要催化剂。随着这些健康状况变得更加普遍，对有效的诊断和治疗方案的需求不断增加。核子造影技术，特别是正子断层扫描（PET）和单光子发射电脑断层扫描（SPECT）在这些疾病的早期检测和治疗计划中发挥着至关重要的作用。

日本是全球预期寿命最高的国家之一。自 20 世纪中叶以来，随着传染病死亡率的下降，预期寿命的增加可归因于多种因素。其中包括由于全民健康保险而可以获得的先进医疗技术、定期健康检查和心血管疾病和癌症筛检等公共卫生倡议，以及坚持传统饮食和健康的生活方式。

然而，心血管疾病和癌症带来的挑战仍然严峻，并且在日本呈上升趋势。儘管这些疾病的长期患者预后有了显着改善，但癌症仍然是死亡的主要原因，紧随其后的是心血管疾病。此外，这些疾病的发生率正在增加，特别是在老龄化人口中，这引起了人们对癌症治疗引起的心血管併发症的担忧，这些併发症可能会影响患者和倖存者的临床结果和生活质量。

随着癌症治疗的进展，核医市场越来越重视标靶放射性药物 (TRP)，以应对一系列肿瘤学和非肿瘤学应用。 TRP 是由多种成分组成的先进治疗剂，包括靶向分子、连接剂、螯合剂和放射性核素，它们共同作用，直接向表达特定分子标靶的细胞提供集中治疗。

根据世界卫生组织 2022 年的资料，日本的癌症统计数据揭示了重大的公共卫生挑战，新增病例 1,005,157 例，死亡 426,278 例，流行病例 2,741,718 例（过去五年）。随着对先进核医学解决方案的需求不断增长，该市场的利益相关者必须优先考虑创新、研究和合作，以有效满足这些紧迫的医疗保健需求。

此外，关键参与者的策略（例如伙伴关係和合作）将推动日本核医学市场。例如，2023 年 3 月，国际原子能总署 (IAEA) 最近与日本大学和科研机构的 11 名成员组成的联盟签署了一项协议，作为其「希望之光」倡议的一部分。该倡议旨在增强亚太地区的核医学队伍，满足该地区日益增长的改善癌症护理的需求。

此外，2023 年 3 月，专注于核医学的日本新创企业 Advanced Medical Science-Planning (AMS) 宣布与京都大学开展一项合作研究计画。此次合作旨在将 Gallium-68 DOTATOC (68Ga-DOTATOC)（一种针对生长抑素受体的放射性药物）引入日本医疗保健市场。这些因素都对日本核子医学市场提出了需求。

此外，对标靶放射性药物开发的需求不断增长，有助于日本核医学市场的扩张。

放射性药物成本高

与核子医学程序（包括影像和治疗技术）相关的高成本对患者的可及性构成了重大障碍。核子医学手术会产生各种成本，例如先进影像设备（如 PET 和 SPECT 机器）、放射性药物的生产和采购以及专业设施的营运费用。这些手术的费用可能从数百美元到数千美元不等，具体取决于其复杂程度和类型。这种定价的可变性可能会阻碍患者进行必要的诊断测试或治疗。

据报道，诊断影像、放射学和核子医学设备的平均价格为 58,657 美元。该数字反映了与获取医疗诊断中使用的各种类型的影像技术相关的一般成本。

高昂的费用可能会限制患者的就诊，特别是来自低收入背景或医疗资源有限地区的患者。许多患者可能难以支付自付费用，或者可能没有足够的核医手术保险，导致在获得重要诊断和治疗服务方面存在不平等。

核子医学经常与 MRI 和 CT 扫描等其他影像技术竞争，儘管这些技术成本高昂，但可能被认为是更实惠的选择。此外，相信非辐射影像方法更安全可以进一步减少对核医学服务的需求，特别是在对成本敏感的人群中。因此，上述因素可能限制日本核医市场的潜在成长。

目录

第 1 章：方法与范围

第 2 章：定义与概述

第 3 章：执行摘要

第 4 章：动力学

  • 影响因素
    • 司机
      • 癌症和心臟病的盛行率不断增加
    • 限制
      • 放射性药物成本高
    • 机会
    • 影响分析

第 5 章：产业分析

  • 波特五力分析
  • 供应链分析
  • 定价分析
  • 专利分析
  • 监管分析
  • SWOT分析
  • 未满足的需求

第 6 章：依产品类型

  • 通用和诊断设备
  • 诊断
    • 单光子发射电脑断层扫描 (SPECT)
    • 锝-99m (Tc-99m)
    • 铊-201 (Tl-201)
    • 镓 67 (Ga-67)
    • 碘 123 (I-123)
    • 其他的
    • 正子断层扫描 (PET)
    • 氟18 (F-18)
    • 铷-82 (Rb-82)
    • 其他的
  • 疗法
    • 阿尔法发射器
    • 镭223 (Ra-223)
    • 其他的
    • 贝塔发射器
    • 碘 131 (I-131)
    • 钇90 (Y-90)
    • 镥 177 (Lu-177)
    • 其他的
    • 近距离放射治疗同位素
    • 铯131
    • 碘125
    • 钯103
    • 铱192
    • 其他的

第 7 章：透过程序容量评估

  • 诊断程序
    • SPECT 程式
    • 正子断层扫描程序
  • 治疗程序

第 8 章：按申请

  • 心臟病学
  • 肿瘤学
  • 神经病学
  • 甲状腺疾病
  • 内分泌肿瘤
  • 淋巴瘤和骨转移
  • 肺部扫描
  • 泌尿科
  • 其他的

第 9 章：最终用户

  • 医院
  • 诊断中心
  • 其他的

第 10 章：竞争格局

  • 竞争场景
  • 市场定位/份额分析
  • 併购分析

第 11 章：公司简介

  • GE Healthcare
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
  • Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
  • Siemens Healthineers
  • Bracco
  • CANON MEDICAL SYSTEMS CORPORATION
  • Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
  • ATOX CO., Ltd.
  • IBA Radiopharma Solutions
  • JFE Engineering Corporation
  • Koninklijke Philips NV

第 12 章：附录

简介目录
Product Code: PH8821

Overview

The Japan nuclear medicine market reached US$ 550.3 million in 2023 and is expected to reach US$ 2,543.2 million by 2031, growing at a CAGR of 21.2 % during the forecast period 2024-2031.

Nuclear medicine is a medical specialty that utilizes radioactive tracers, known as radiopharmaceuticals, to evaluate bodily functions and diagnose or treat diseases. Specialized imaging cameras enable physicians to monitor the movement of these radioactive tracers within the body. The two most prevalent imaging techniques in nuclear medicine are Single Photon Emission Computed Tomography (SPECT) and Positron Emission Tomography (PET) scans.

SPECT imaging devices generate three-dimensional (tomographic) images showing the distribution of radioactive tracer molecules introduced into a patient's body. These 3D images are created by computer processing a multitude of projection images captured from various angles around the body. SPECT imagers are equipped with gamma camera detectors that can identify the gamma-ray emissions from the tracers that have been administered to the patient.

PET scans also utilize radiopharmaceuticals to generate three-dimensional images. The primary distinction between SPECT and PET scans lies in the types of radiotracers employed. SPECT scans detect gamma rays, whereas the radiotracers used in PET scans produce small particles known as positrons upon decay. A positron is a particle that has a mass similar to that of an electron but carries an opposite charge. These factors have driven Japan nuclear medicine market expansion.

Market Dynamics: Drivers & Restraints

Increasing Prevalence of Cancer and Cardiac Disorders

The increasing prevalence of cancer and cardiac disorders is significantly driving the growth of the Japan nuclear medicine market and is expected to drive throughout the market forecast period.

The increasing incidence of cancer and cardiovascular diseases serves as a significant catalyst for the groth of the nuclear medicine market. As these health conditions become more widespread, there is a rising demand for effective diagnostic and therapeutic options. Nuclear imaging techniques, particularly Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) play a crucial role in the early detection and treatment planning for these diseases.

Japan boasts one of the highest life expectancies globally. The improvement in life expectancy since the mid-20th century, following a decline in mortality from communicable diseases, can be attributed to various factors. These include advanced medical technologies that are accessible due to universal health insurance, public health initiatives like routine health check-ups and screenings for cardiovascular diseases and cancer, and adherence to a traditional diet along with a healthy lifestyle.

However, the challenges posed by cardiovascular diseases and cancer remain significant and are on the rise in Japan. Despite notable improvements in long-term patient outcomes for these conditions, cancer continues to be the leading cause of death, followed closely by cardiovascular diseases. Furthermore, the incidence of these diseases is increasing, particularly among the aging population, raising concerns about cardiovascular complications resulting from cancer treatments that can affect clinical outcomes and quality of life for patients and survivors.

As cancer treatment progresses, the nuclear medicine market is placing greater emphasis on targeted radiopharmaceuticals (TRPs) to tackle a range of oncology and non-oncology applications. TRPs are advanced therapeutic agents that consist of multiple components, including a targeting molecule, linker, chelating agent, and radionuclide, which work together to deliver focused treatment directly to cells that express specific molecular targets.

According to the WHO data in 2022, in Japan, the cancer statistics reveal a significant public health challenge, with 1,005,157 new cases, 426,278 deaths, and 2,741,718 prevalent cases (over the past five years). As the demand for advanced nuclear medicine solutions rises, stakeholders in this market must prioritize innovation, research, and collaboration to effectively address these urgent healthcare needs.

Furthermore, key player's strategies such as partnerships and collaborations would drive the Japan nuclear medicine market. For instance, in March 2023, the International Atomic Energy Agency (IAEA) recently signed an agreement with an 11-member consortium of universities and scientific institutions in Japan as part of its Rays of Hope initiative. This initiative aims to enhance the nuclear medicine workforce across Asia and the Pacific, addressing the growing need for improved cancer care in the region.

Also, in March 2023, Advanced Medical Science-Planning (AMS), a Japanese start-up focused on nuclear medicine, announced a collaborative research initiative with Kyoto University. This partnership aims to introduce Gallium-68 DOTATOC (68Ga-DOTATOC), a radiopharmaceutical that targets somatostatin receptors, into the Japanese healthcare market. All these factors demand the Japan nuclear medicine market.

Moreover, the rising demand for the development of targeted radiopharmaceuticals contributes to Japan nuclear medicine market expansion.

High Cost of Radiopharmaceuticals

The high costs associated with nuclear medicine procedures, including imaging and therapeutic techniques, present a significant barrier to patient accessibility. Nuclear medicine procedures incur various costs, such as those for advanced imaging equipment (like PET and SPECT machines), the production and acquisition of radiopharmaceuticals, and the operational expenses of specialized facilities. The costs for these procedures can range from several hundred to several thousand dollars, depending on their complexity and type. This variability in pricing can discourage patients from pursuing necessary diagnostic tests or treatments.

The average price of diagnostic imaging, radiology, and nuclear medicine equipment is reported to be $58,657. This figure reflects the general cost associated with acquiring various types of imaging technology used in medical diagnostics.

The elevated costs can restrict access for patients, particularly those from lower-income backgrounds or in areas with limited healthcare resources. Many patients may struggle to cover out-of-pocket expenses or may not have sufficient insurance coverage for nuclear medicine procedures, leading to inequities in access to vital diagnostic and therapeutic services.

Nuclear medicine often competes with other imaging techniques like MRI and CT scans, which might be perceived as more affordable options despite their costs. Additionally, the belief that non-radiation-based imaging methods are safer can further decrease demand for nuclear medicine services, especially among cost-sensitive populations. Thus, the above factors could be limiting the Japan nuclear medicine market's potential growth.

Segment Analysis

The Japan nuclear medicine market is segmented based on product type, procedural volume assessment, application, and end-user.

Product Type:

The diagnostics segment is expected to dominate the Japan nuclear medicine market share

The diagnostics segment holds a major portion of the Japan nuclear medicine market share and is expected to continue to hold a significant portion of the Japan nuclear medicine market share during the forecast period.

The diagnostics segment of the Japan nuclear medicine market is a vital area that includes various imaging techniques and radiopharmaceuticals essential for detecting and managing diseases, particularly cancer. This segment prominently features Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT), both crucial for accurately identifying tumors, evaluating their progression, and formulating treatment plans.

For instance, F-18 PSMA-1007 PET has emerged as a cutting-edge diagnostic tool specifically designed to detect prostate cancer recurrence and metastasis with high precision. This imaging agent has demonstrated superior detection capabilities compared to traditional methods like CT and bone scintigraphy, underscoring its importance in oncology diagnostics.

Institutions such as St. Luke's MediLocus provide comprehensive PET-CT scan screenings aimed at early cancer detection. These screenings are critical since early diagnosis significantly enhances treatment outcomes. The integration of PET and CT in one system improves imaging quality, facilitating better visualization of tumors.

The ongoing development of new radiopharmaceuticals is expanding the diagnostic capabilities of nuclear medicine. Research into various PET and SPECT tracers is enhancing the visualization of tumor metabolism, receptor activity, and brain function, thereby broadening the scope of nuclear medicine applications.

Furthermore, key players in the country strategies such as partnerships and collaborations would drive this segment growth in the Japan nuclear medicine market. For instance, in October 2024, Curium announced a strategic partnership with PDRadiopharma Inc., a wholly-owned subsidiary of PeptiDream. This collaboration focuses on the clinical development, regulatory filing, and commercialization in Japan of two key radiopharmaceutical agents: 177Lu-PSMA-I&T and 64Cu-PSMA-I&T.

Both agents are designed to target the prostate-specific membrane antigen (PSMA), which is expressed on prostate cancer cells, making them significant for both treatment and diagnostic purposes in prostate cancer management. These factors have solidified the segment's position in the Japan nuclear medicine market.

Competitive Landscape

The major players in the Japan nuclear medicine market include GE Healthcare, Fujifilm (FUJIFILM Toyama Chemical Co. Ltd), Siemens Healthineers, Bracco, CANON MEDICAL SYSTEMS CORPORATION, Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd), ATOX CO., Ltd., IBA Radiopharma Solutions, JFE Engineering Corporation, and Koninklijke Philips N.V. among others.

Key Developments

  • In November 2024, Akio Ohta, a researcher from Chiyoda Technol Corporation (CTC) in Japan, stated that the company has been collaborating with the National Research and Innovation Agency (BRIN) on the development of extraction technology for Molybdenum-99 (Mo-99) and Technetium-99m (Tc-99m). This collaboration is facilitated through the Japan Atomic Energy Agency (JAEA), indicating a strategic partnership aimed at enhancing the production and availability of these critical isotopes used in nuclear medicine.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Japan nuclear medicine market report delivers a detailed analysis with 40+ key tables, more than 30 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Procedural Volume Assessment & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Procedural Volume Assessment
  • 3.3. Snippet by Application
  • 3.4. Snippet by End-User

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing Prevalence of Cancer and Cardiac Disorders and
    • 4.1.2. Restraints
      • 4.1.2.1. High Cost of Radiopharmaceuticals
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Patent Analysis
  • 5.5. Regulatory Analysis
  • 5.6. SWOT Analysis
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. General and Diagnostic Equipment*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Diagnostics
    • 6.3.1. Single Photon Emission Computed Tomography (SPECT)
    • 6.3.2. Technetium-99m (Tc-99m)
    • 6.3.3. Thallium-201 (Tl-201)
    • 6.3.4. Gallium-67 (Ga-67)
    • 6.3.5. Iodine-123 (I-123)
    • 6.3.6. Others
    • 6.3.7. Positron Emission Tomography (PET)
    • 6.3.8. Fluorine-18 (F-18)
    • 6.3.9. Rubidium-82 (Rb-82)
    • 6.3.10. Others
  • 6.4. Therapeutics
    • 6.4.1. Alpha Emitters
    • 6.4.2. Radium-223 (Ra-223)
    • 6.4.3. Others
    • 6.4.4. Beta Emitters
    • 6.4.5. Iodine-131 (I-131)
    • 6.4.6. Yttrium-90 (Y-90)
    • 6.4.7. Lutetium-177 (Lu-177)
    • 6.4.8. Others
    • 6.4.9. Brachytherapy Isotopes
    • 6.4.10. Cesium-131
    • 6.4.11. Iodine-125
    • 6.4.12. Palladium-103
    • 6.4.13. Iridium-192
    • 6.4.14. Others

7. By Procedural Volume Assessment

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Procedural Volume Assessment
    • 7.1.2. Market Attractiveness Index, By Procedural Volume Assessment
  • 7.2. Diagnostic Procedures*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 7.2.3. SPECT Procedures
    • 7.2.4. PET Procedures
  • 7.3. Therapeutic Procedures

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Cardiology*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oncology
  • 8.4. Neurology
  • 8.5. Thyroid Disorders
  • 8.6. Endocrine Tumors
  • 8.7. Lymphoma and Bone Metastasis
  • 8.8. Pulmonary Scans
  • 8.9. Urology
  • 8.10. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Diagnostic Centers
  • 9.4. Others

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. GE Healthcare*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Fujifilm (FUJIFILM Toyama Chemical Co. Ltd)
  • 11.3. Siemens Healthineers
  • 11.4. Bracco
  • 11.5. CANON MEDICAL SYSTEMS CORPORATION
  • 11.6. Nihon Medi-Physics Co. (Sumitomo Chemical Co. Ltd)
  • 11.7. ATOX CO., Ltd.
  • 11.8. IBA Radiopharma Solutions
  • 11.9. JFE Engineering Corporation
  • 11.10. Koninklijke Philips N.V.

LIST NOT EXHAUSTIVE

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us